IL6 and Parkinson disease: The research also demonstrated that in the case of subacute and chronic PD mice models, PLB effectively inhibits inflammatory pathway activation via the TLR/NF-κB pathway and decreases the expression of TNF-α, IL-6, and IL-1βmRNA, thus providing neuroprotection.